AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
55.16
-0.54 (-0.97%)
At close: Sep 10, 2026, 4:00 PM EDT
54.39
-0.77 (-1.40%)
After-hours: Sep 10, 2026, 5:36 PM EDT
AnaptysBio Revenue
AnaptysBio had revenue of $25.56M in the quarter ending March 31, 2026, a decrease of -7.98%. This brings the company's revenue in the last twelve months to $232.39M, up 107.73% year-over-year. In the year 2025, AnaptysBio had annual revenue of $234.60M with 157.01% growth.
Revenue (ttm)
$232.39M
Revenue Growth
+107.73%
P/S Ratio
6.95
Revenue / Employee
$2,234,500
Employees
104
Market Cap
1.63B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 234.60M | 143.32M | 157.01% |
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
| Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
| Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
| Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
| Dec 31, 2014 | 15.84M | 10.36M | 188.86% |
| Dec 31, 2013 | 5.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Novavax | 413.80M |
| Syndax Pharmaceuticals | 252.25M |
| Apnimed | 120.15M |
| Septerna | 98.88M |
| Ascentage Pharma Group International | 94.61M |
| Inhibrx Biosciences | 1.30M |
ANAB News
- 9 days ago - Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 16 days ago - AnaptysBio price target lowered to $70 from $75 at TD Cowen - TheFly
- 1 month ago - AnaptysBio falls -10.8% - TheFly
- 2 months ago - AnaptysBio Proxy statement: Proxy filing - Filings
- 2 months ago - AnaptysBio Proxy statement: Proxy filing - Filings
- 3 months ago - AnaptysBio assumed with a Buy at H.C. Wainwright - TheFly
- 3 months ago - AnaptysBio price target raised to $90 from $85 at Leerink - TheFly
- 4 months ago - AnaptysBio price target raised to $76 from $60 at UBS - TheFly